XTalks

NOVEMBER 4, 2020

It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. They reported their findings last week in the journal Science.

Allergies 98

Allergies Antibody In-Vitro Development 98

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Vaccination 130

Vaccination Vaccine Containment Immune Response 130

XTalks

JULY 14, 2021

CDIs typically develop after the use of antibiotics, which can wipe out the gut’s healthy bacteria. Seres’ microbiome drug SER-109 aims to restore the healthy bacteria via an oral capsule that contains a protective species of gut bacteria. Difficile infection (CDI). Read the full articles here: .

Bacteria 52

Bacteria Marketing Drugs Containment 52

Pfizer

FEBRUARY 16, 2023

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is a surface protein expressed by the bacteria when present in a tick. FDA in July 2017.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

The Pharma Data

OCTOBER 19, 2020

Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. There are more than 90 different types of pneumococcal bacteria which can affect adults differently than children. Food and Drug Administration before the end of the year, remain on track.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

The Pharma Data

DECEMBER 13, 2020

Both patients experienced disease progression on immunotherapy with anti- PD-1/PDL-1 antibodies prior to enrollment in the study. The forward-looking statements contained in this press release reflect Synlogic’s current views with respect to future events. Sokolovska, A., Nature Communications 11, 2739 (2020)).

Immune Response 40

Immune Response Engineer Medicine Clinical Trials 40

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162